Round Table Services LLC continued to hold its position in Inovio Pharmaceuticals Inc (NASDAQ:INO) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,500 shares of the biopharmaceutical company’s stock at the end of the first quarter. Round Table Services LLC’s holdings in Inovio Pharmaceuticals were worth $857,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of INO. Vident Investment Advisory LLC raised its position in Inovio Pharmaceuticals by 67.5% in the fourth quarter. Vident Investment Advisory LLC now owns 106,147 shares of the biopharmaceutical company’s stock valued at $737,000 after buying an additional 42,764 shares during the period. Thomas J. Herzfeld Advisors Inc. bought a new position in Inovio Pharmaceuticals during the fourth quarter valued at about $104,000. ARK Investment Management LLC bought a new position in Inovio Pharmaceuticals during the fourth quarter valued at about $217,000. Keybank National Association OH raised its position in Inovio Pharmaceuticals by 6.9% in the fourth quarter. Keybank National Association OH now owns 30,242 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 1,950 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in Inovio Pharmaceuticals during the fourth quarter valued at about $559,000. Institutional investors own 28.72% of the company’s stock.
Inovio Pharmaceuticals Inc (NASDAQ:INO) traded up 0.3295% during midday trading on Thursday, hitting $6.1201. The company had a trading volume of 363,280 shares. The company’s market cap is $453.51 million. The firm has a 50-day moving average price of $6.37 and a 200-day moving average price of $7.01. Inovio Pharmaceuticals Inc has a 12 month low of $5.83 and a 12 month high of $11.69.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, March 15th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.06. The business earned $8.50 million during the quarter, compared to analyst estimates of $5.21 million. Inovio Pharmaceuticals had a negative net margin of 199.99% and a negative return on equity of 39.93%. The firm’s quarterly revenue was up 44.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.07 earnings per share. Equities analysts anticipate that Inovio Pharmaceuticals Inc will post ($1.09) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.wkrb13.com/markets/2065238/round-table-services-llc-maintains-stake-in-inovio-pharmaceuticals-inc-ino.html.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Aegis restated a “buy” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, March 21st. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 16th. Maxim Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Thursday, March 16th. Finally, Piper Jaffray Companies lowered Inovio Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $13.00 to $9.00 in a research note on Thursday, March 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $12.10.
In other news, Director Morton Collins acquired 21,300 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Monday, March 27th. The stock was purchased at an average cost of $6.25 per share, with a total value of $133,125.00. Following the completion of the acquisition, the director now owns 142,291 shares in the company, valued at approximately $889,318.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jong Joseph Kim sold 147,180 shares of Inovio Pharmaceuticals stock in a transaction on Friday, March 31st. The stock was sold at an average price of $6.54, for a total value of $962,557.20. Following the transaction, the chief executive officer now directly owns 2,164,887 shares of the company’s stock, valued at $14,158,360.98. The disclosure for this sale can be found here. 9.90% of the stock is owned by company insiders.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals Inc (NASDAQ:INO).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065238/round-table-services-llc-maintains-stake-in-inovio-pharmaceuticals-inc-ino.html
Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.